Companies Adicet Bio, Inc.
Adicet Bio (ACET): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Adicet Bio, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $5,973,807FY2023
- $4,644,366FY2024
- $1,465,747FY2025
CEO total pay was $1,465,747 in fiscal 2025, down from $4,644,366 in fiscal 2024.
FY2025: salary $646,294 · bonus $0 · stock awards $0 · option awards $512,079
Order ACET
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chen Schor | $646,294 | $0 | $0 | $512,079 | $284,592 | $0 | $22,782 | $1,465,747 |
| President and Chief Executive Officer | ||||||||
| Julia Maltzman | 452,308 | 0 | 0 | 502,605 | 153,600 | 0 | 16,290 | 1,124,803 |
| Chief Medical Officer (6) | ||||||||
| Blake Aftab | 484,720 | 0 | 0 | 184,367 | 155,232 | 0 | 91,170 | 915,489 |
| Chief Scientific Officer and Senior Vice President | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Chen Schor | $1,465,747 | $4,644,366 | $5,973,807 | ↓ −3,178,619 |
| Julia Maltzman | 1,124,803 | — | — | — |
| Blake Aftab | 915,489 | 1,473,576 | — | ↓ −558,087 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company aims to align the interests of named executive officers with those of stockholders and motivate contributions to performance through equity grants with vesting requirements that promote retention. Compensation is set based on market comparables, individual performance, and a desire to achieve short- and long-term results in the best interests of stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Blake Aftab | Option | 309 | 34.24 | — |
| Blake Aftab | RSU | 543 | — | 4,572 |
| Blake Aftab | RSU | 820 | — | 6,904 |
| Chen Schor | RSU | 1,781 | — | 14,996 |
| Blake Aftab | Option | 1,976 | 34.24 | — |
| Chen Schor | RSU | 2,928 | — | 24,654 |
| Blake Aftab | Option | 7,840 | 38.4 | — |
| Blake Aftab | Option | 10,959 | 40.48 | — |
| Blake Aftab | Option | 13,246 | 14.16 | — |
| Julia Maltzman | Option | 35,156 | 14.24 | — |
| Chen Schor | Option | 36,793 | 14.24 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew SinclairIndependent | $76,681 | $4,630 | $15,715 | — | — | $97,027 |
| Steve DubinIndependent | 61,761 | 4,630 | 15,715 | — | — | 82,106 |
| Jeffrey ChodakewitzIndependent | 48,530 | 4,630 | 15,715 | — | — | 68,876 |
| Katie PengIndependent | 47,500 | 4,630 | 15,715 | — | — | 67,845 |
| Michael GrissingerIndependent | 31,772 | 0 | 27,859 | — | — | 59,631 |
| Aya JakobovitsIndependent | 20,151 | 0 | 15,611 | — | — | 35,762 |
| Carl L. GordonIndependent | 23,736 | 0 | 0 | — | — | 23,736 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $310,131 |
| Equity awards (grant-date value) | $18,520 |
| All other compensation | $0 |
| Total cost of the board | $328,651 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Adicet Bio as a peer
Companies that benchmark against ACET
5 companies name ACET as a compensation peer
- Astria Therapeutics, Inc.ATXSFY2024
- C4 Therapeutics, Inc.CCCCFY2025
- Editas Medicine, Inc.EDITFY2025
- Generation Bio Co.GBIOFY2024
- Mersana Therapeutics, Inc.MRSNFY2024
Each company listed discloses ACET in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ACET in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Adicet Bio, Inc. | 2025 | Chen Schor | $646,294 | $0 | $512,079 | $284,592 | $1,465,747 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 4,611,540 | 745,537 | 4,939 | 86.08% | Passed |
| 2023 | 2023-06-01 | — | — | — | — | — |
| 2022 | 2022-06-02 | — | — | — | — | — |
| 2021 | 2021-04-27 | — | — | — | — | — |
| 2020 | 2020-06-03 | — | — | — | — | — |
| 2019 | 2019-05-08 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 86.08%a |
| 2023 | 2023-06-01 | —b |
| 2022 | 2022-06-02 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Chen Schor. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,465,747. View filing ↗
- Section 01, Julia Maltzman. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 1,124,803. View filing ↗
- Section 01, Blake Aftab. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 915,489. View filing ↗
- Section 08, Andrew Sinclair. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 97,027. View filing ↗
- Section 08, Steve Dubin. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 82,106. View filing ↗
- Section 08, Jeffrey Chodakewitz. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 68,876. View filing ↗
- Section 08, Katie Peng. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 67,845. View filing ↗
- Section 08, Michael Grissinger. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 59,631. View filing ↗
- Section 08, Aya Jakobovits. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 35,762. View filing ↗
- Section 08, Carl L. Gordon. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 23,736. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 86.08% (votes for as printed: 4,611,540). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-05. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-03. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 310,131 + equity 18,520 + all other 0 = 328,651, summed across the director compensation table rows.
- Adicet Bio, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Adicet Bio, Inc.'s own proxy. As printed: 1,465,747. View filing ↗